

ONLINE

2ND IMI AMR ACCELERATOR ANNUAL MEETING


28 September 2021, 13:00 – 17:00 (CEST)

Draft Agenda:

Time (CEST)	Session details
13:00 – 13:05	Welcome and opening of the meeting <i>By Karen O'Dwyer, COMBINE Project Leader, GSK & Anders Karlen, COMBINE Project Coordinator, Uppsala University</i>
13:05 – 13:25	Support and solutions offered by COMBINE <i>By Philipp Gribbon, COMBINE Data Manager, Fraunhofer ITMP</i>
13:25 – 13:40	Introduction to new AMR Accelerator project: UNITE4TB + Q&A <i>By Martin Boeree, UNITE4TB Project Coordinator, Stichting Radboud Universitair Medisch Centrum</i>
<i>On stage: AMR Accelerator projects – A year in review: main achievements and challenges</i>	
13:40 – 13:50	RespiriTb & RespiriNTM
13:50 – 14:00	TRIC-TB
14:00 – 14:10	ERA4TB
14:10 – 14:20	GNA NOW
14:20 – 14:30	AB-Direct
14:30 – 14:40	COMBINE
14:40 – 15:00	Coffee break
15:00 – 15:50	Breakout sessions – four parallel virtual roundtables <ul style="list-style-type: none"> ➤ Effective administrative management of IMI projects – Presentation by IMI with Q&A <i>Moderated by Anna Lobell, COMBINE Finance Manager, Uppsala University</i> ➤ Conduct of clinical studies in a global pandemic – sharing experience and learnings <i>Moderated by Karen O'Dwyer, COMBINE Project Leader, GSK</i> ➤ Data management – experience, learnings and tips <i>Moderated by Philipp Gribbon, COMBINE Data Manager, Fraunhofer ITMP</i> ➤ The value of hollow fiber analysis and other dynamic models in AMR drug development <i>Moderated by Frederik Deroose, COMBINE Portfolio Manager, Asclepia Outsourcing Solutions</i>

Time (CEST)	Session details
15:50 - 16:20	Keynote presentation by Lindsay McKenna, TB Project Co-Director, Treatment Action Group: <i>Community Engagement in TB Research, A Crash Course</i>
16:20 - 16:50	Q&A with Lindsay McKenna <i>Moderated by Diarmaid Hughes, COMBINE Scientific Advisor, Uppsala University</i>
16:50 - 17:00	Wrap-up & Farewell

Please note that the schedule is subject to modifications. You will be kept informed in case of any further updates.



IMI Associated Partners for ERA4TB



SPONSORED BY THE



IMI Associated Partners for UNITE4TB



The AMR Accelerator receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853976 | 853967 | 853979 | 853932 | 853903 | 853800 | 853989 | 101007873. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. ERA4TB receives additional support from Global Alliance for TB Drug Development, Bill & Melinda Gates Foundation and University of Dundee. UNITE4TB has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research.